Biomea's Icovamenib Boosts Insulin Production 52% in Type 1 Diabetes Trial

(Bloomberg) -- Biomea Fusion’s experimental drug, icovamenib, produced a 52 percent increase in natural insulin secretion in a small group of type 1 diabetes patients after 12 weeks, with the effect largely persisting for a year, suggesting a potential new way to treat the autoimmune disease.

"Any evidence of improvement in endogenous insulin secretion even among a few T1D individuals is unprecedented and of immense biologic and clinical significance," G. Alexander Fleming, a former FDA senior medical officer involved in the review of landmark diabetes therapies, said in a statement. "These findings warrant rigorous and longer-term evaluation."

In the Phase 2 COVALENT-112 trial, five patients with type 1 diabetes diagnosed within the last three years saw their mean C-peptide levels—a direct marker of insulin production—rise by 52 percent from baseline after receiving a 200 mg daily dose for 12 weeks (p < 0.001). After treatment stopped, the benefit proved durable, with C-peptide levels at 52 weeks showing only a 7 percent decline from the study's start, a stark contrast to the typical progressive decline seen in the disease.

The results position icovamenib as a potential disease-modifying therapy that aims to regenerate the body's own insulin-producing beta cells, rather than just managing glucose with external insulin or suppressing the immune system. Biomea Fusion (NASDAQ: BMEA) now plans to launch a larger, longer-duration Phase 2 trial in the second half of this year to confirm the findings, a critical step for the clinical-stage company that could challenge existing treatment paradigms.

A Closer Look at the COVALENT-112 Data

The COVALENT-112 study was an open-label trial designed as a proof-of-concept, enrolling adult patients with established Stage 3 type 1 diabetes. It featured two main cohorts: patients diagnosed within the last three years and those with longer-standing disease of 3-15 years.

A clear dose-response was observed, with the 200 mg dose showing significantly greater activity than a 100 mg dose. In patients with longer-standing disease, C-peptide levels were generally preserved through the 52-week observation period. The company reported the drug was generally well tolerated.

However, the trial’s scope was limited. Study enrollment was interrupted in May 2024 due to an FDA clinical hold that has since been resolved. Consequently, the data reflects about half of the intended patient population, and a planned placebo-controlled second part of the study was not completed. The small sample size (n=5 for the primary result) means the findings, while statistically significant, must be replicated in a larger patient group.

A New Mechanism for Type 1 Diabetes?

Icovamenib works by inhibiting menin, a protein thought to act as a brake on the growth and turnover of pancreatic beta cells. By temporarily suppressing menin, the oral therapy is designed to allow these crucial insulin-producing cells to regenerate and restore function. This approach is fundamentally different from the two mainstays of current T1D management.

Most patients rely on lifelong insulin replacement, delivered via injections or automated insulin delivery (AID) systems like the recently cleared Control-IQ+ technology from Tandem Diabetes Care. While these systems improve glycemic control, they do not alter the underlying disease. Other investigational therapies focus on suppressing the autoimmune attack that destroys beta cells.

Biomea’s strategy, if successful in larger trials, could offer a short course of oral therapy that produces a lasting biological effect. The company plans to explore whether extending dosing to six or 12 months, and potentially adding an immunosuppressive agent, could further enhance clinical outcomes in its next trial, which will be conducted with leading research centers including the Joslin Diabetes Center and the Barbara Davis Center for Diabetes. The company has an active Form S-3 shelf registration, providing flexibility to fund these future studies.

This article is for informational purposes only and does not constitute investment advice.